3.61 USD
+0.02 (+0.56%)
We assign a fundamental rating of 2 out of 10 to EVO. EVO was compared to 58 industry peers in the Life Sciences Tools & Services industry. EVO has a bad profitability rating. Also its financial health evaluation is rather negative. EVO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- EVO had negative earnings in the past year.
- EVO had a positive operating cash flow in the past year.
- In multiple years EVO reported negative net income over the last 5 years.
- Each year in the past 5 years EVO had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -8.97%, EVO is in line with its industry, outperforming 45.61% of the companies in the same industry.
- EVO has a Return On Equity (-19.87%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.97% | ||
| ROE | -19.87% | ||
| ROIC | N/A |
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a Gross Margin value of 10.82%, EVO is not doing good in the industry: 87.72% of the companies in the same industry are doing better.
- EVO's Gross Margin has declined in the last couple of years.
- EVO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 10.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
2. Health
2.1 Basic Checks
- EVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for EVO has been increased compared to 1 year ago.
- The number of shares outstanding for EVO has been increased compared to 5 years ago.
- The debt/assets ratio for EVO has been reduced compared to a year ago.
2.2 Solvency
- EVO has an Altman-Z score of 0.57. This is a bad value and indicates that EVO is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of 0.57, EVO is not doing good in the industry: 71.93% of the companies in the same industry are doing better.
- EVO has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.48, EVO is not doing good in the industry: 64.91% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.57 |
ROIC/WACCN/A
WACC7.75%
2.3 Liquidity
- EVO has a Current Ratio of 2.12. This indicates that EVO is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 2.12, EVO perfoms like the industry average, outperforming 42.11% of the companies in the same industry.
- A Quick Ratio of 2.03 indicates that EVO has no problem at all paying its short term obligations.
- The Quick ratio of EVO (2.03) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 2.03 |
3. Growth
3.1 Past
- EVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -136.17%.
- EVO shows a decrease in Revenue. In the last year, the revenue decreased by -2.67%.
- The Revenue has been growing by 12.29% on average over the past years. This is quite good.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)-2.67%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-11.36%
3.2 Future
- Based on estimates for the next years, EVO will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.42% on average per year.
- EVO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.78% yearly.
EPS Next Y50.73%
EPS Next 2Y35.51%
EPS Next 3Y27.78%
EPS Next 5Y18.42%
Revenue Next Year-2.93%
Revenue Next 2Y2.64%
Revenue Next 3Y5.43%
Revenue Next 5Y4.78%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- EVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- EVO's Enterprise Value to EBITDA is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 684.43 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as EVO's earnings are expected to grow with 27.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.51%
EPS Next 3Y27.78%
5. Dividend
5.1 Amount
- EVO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EVOTEC SE - SPON ADR / EVO FAQ
Can you provide the ChartMill fundamental rating for EVOTEC SE - SPON ADR?
ChartMill assigns a fundamental rating of 2 / 10 to EVO.
Can you provide the valuation status for EVOTEC SE - SPON ADR?
ChartMill assigns a valuation rating of 1 / 10 to EVOTEC SE - SPON ADR (EVO). This can be considered as Overvalued.
How profitable is EVOTEC SE - SPON ADR (EVO) stock?
EVOTEC SE - SPON ADR (EVO) has a profitability rating of 2 / 10.
What is the financial health of EVOTEC SE - SPON ADR (EVO) stock?
The financial health rating of EVOTEC SE - SPON ADR (EVO) is 3 / 10.
What is the earnings growth outlook for EVOTEC SE - SPON ADR?
The Earnings per Share (EPS) of EVOTEC SE - SPON ADR (EVO) is expected to grow by 50.73% in the next year.